These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Immunological aspects of melanoma]. Sjögren H Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045 [No Abstract] [Full Text] [Related]
3. Self-recognition and tumor response to immunotherapy. Ernstoff MS J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939 [No Abstract] [Full Text] [Related]
4. [Immunotherapy for melanoma: how can tolerance be overcome?]. Robert C Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031 [No Abstract] [Full Text] [Related]
15. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunotherapy in the treatment of melanoma. Faries MB Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223 [TBL] [Abstract][Full Text] [Related]
17. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Hsueh EC; Morton DL Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158 [TBL] [Abstract][Full Text] [Related]
18. [Immunology of malignant melanoma]. Misgeld V Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321 [No Abstract] [Full Text] [Related]
19. Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585 [TBL] [Abstract][Full Text] [Related]
20. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look. Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371 [No Abstract] [Full Text] [Related] [Next] [New Search]